U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H19N.C6H12O7
Molecular Weight 433.4947
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETIFELMINE GLUCONATE

SMILES

OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.CCC(CN)=C(C1=CC=CC=C1)C2=CC=CC=C2

InChI

InChIKey=HXSORIGWWKXLDZ-IFWQJVLJSA-N
InChI=1S/C17H19N.C6H12O7/c1-2-14(13-18)17(15-9-5-3-6-10-15)16-11-7-4-8-12-16;7-1-2(8)3(9)4(10)5(11)6(12)13/h3-12H,2,13,18H2,1H3;2-5,7-11H,1H2,(H,12,13)/t;2-,3-,4+,5-/m.1/s1

HIDE SMILES / InChI
Molecular Formula C6H12O7
Molecular Weight 196.1553
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula C17H19N
Molecular Weight 237.3395
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Gilutensin is a drug that was developed for the treatment of hypotensive circulatory disorders. As there is no information available on the drug since 1970, its development is supposed to be terminated in early phase.

Approval Year

Unknown
149124
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2252
inhibitor
2438
inhibitor
2507
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2C19
2057

CYP1A2
2153
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
2333
 inconclusive [IC50 10.2188 uM]
CYP3A4
2633
 yes [IC50 0.4772 uM]
CYP2C9
2497
 yes [IC50 11.9877 uM]
CYP2D6
2546
 yes [IC50 3.4671 uM]
CYP2C19
2141
 yes [IC50 4.3649 uM]
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
PubMed

PubMed

TitleDatePubMed
[Gilutensin-Heptaminol in vegetative circulatory regulation disorders].
1970-10-23
[Hypotensive effect of gilutensin on surgical patients].
1968-11-03
[EXPERIENCES WITH GILUTENSIN IN CIRCULATORY DISORDERS].
1965-05
[THE TREATMENT OF HYPOTENSIVE CIRCULATORY DISORDERS WITH GILUTENSIN].
1964-08
Patents

Patents

WO2010015029 A1
3
WO2013007698 A1
3

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:53:37 GMT 2025
Edited
by admin
on Mon Mar 31 21:53:37 GMT 2025
Record UNII
44VF23ML3X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
1-BUTANAMINE, 2-(DIPHENYLMETHYLENE)-, D-GLUCONATE
Preferred Name English
ETIFELMINE GLUCONATE
Common Name English
2-ETHYL-3,3-DIPHENYL-2-PROPENYLAMINE GLUCONATE
Common Name English
D-GLUCONIC ACID, COMPD. WITH 2-(DIPHENYLMETHYLENE)-1-BUTANAMINE (1:1)
Systematic Name English
GLUCONIC ACID, D-, COMPD. WITH 2-(DIPHENYLMETHYLENE)BUTYLAMINE (1:1)
Common Name English
BUTYLAMINE, 2-(DIPHENYLMETHYLENE)-, D-GLUCONATE
Common Name English
Code System Code Type Description
FDA UNII
44VF23ML3X
Created by admin on Mon Mar 31 21:53:37 GMT 2025 , Edited by admin on Mon Mar 31 21:53:37 GMT 2025
PRIMARY
EPA CompTox
DTXSID20951262
Created by admin on Mon Mar 31 21:53:37 GMT 2025 , Edited by admin on Mon Mar 31 21:53:37 GMT 2025
PRIMARY
PUBCHEM
206726
Created by admin on Mon Mar 31 21:53:37 GMT 2025 , Edited by admin on Mon Mar 31 21:53:37 GMT 2025
PRIMARY
CAS
28599-37-3
Created by admin on Mon Mar 31 21:53:37 GMT 2025 , Edited by admin on Mon Mar 31 21:53:37 GMT 2025
PRIMARY
Related Record Type Details
Structure of ETIFELMINE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of ETIFELMINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966